Cyclopharm Limited
CYC.ASXHealth Care
The Company produces and supplies the medical profession with proprietary lung radiopharmaceuticals.
Market Data
$0.710
+0.0%$88.2M
-100000.0x
$-0.156
0.00%
-0.2%
Latest Earnings
Preliminary Final Report
25 February 2026
Cyclopharm delivered record revenue of $32.3M (+17.2%) driven by strong US Technegas growth (+226% to $2.7M) and third-party distribution sales (+26%). However, the company posted a larger loss of $17.2M (vs $13.2M prior year) due to strategic investments in US market expansion, with EBITDA loss widening to $15.4M. Key points: Record revenue of $32.3M (+17.2%) with US becoming largest individual Technegas market in first full year; US Technegas revenue surged 226% to $2.7M with 46 revenue-generating sites operational; Third-party distribution business grew strongly (+26% to $15.6M) with consumables and services up 46%
Recent Announcements
Preliminary Final Report
Cyclopharm delivered record revenue of $32.3M (+17.2%) driven by strong US Technegas growth (+226% to $2.7M) and third-party distribution sales (+26%). However, the company posted a larger loss of $17.2M (vs $13.2M prior year) due to strategic investments in US market expansion, with EBITDA loss widening to $15.4M. Key points: Record revenue of $32.3M (+17.2%) with US becoming largest individual Technegas market in first full year; US Technegas revenue surged 226% to $2.7M with 46 revenue-generating sites operational; Third-party distribution business grew strongly (+26% to $15.6M) with consumables and services up 46%
Becoming a substantial holder
Investors Mutual Limited has become a substantial holder in Cyclopharm Limited (ASX: CYC), acquiring 7,067,962 ordinary shares representing 5.86% voting power as of February 12, 2026.
Get real-time alerts for CYC
Receive AI-powered earnings summaries and instant notifications when Cyclopharm Limited releases results.
Register Free